Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

following a review of the company’s 2024 annual report and revised earnings forecasts. The report highlighted stronger-than-expected immunology sales, particularly from the drug Skyrizi.

In Crohn's, Skyrizi, Stelara, and Ilumya are already approved by the FDA, while Tremfya is under review, having been submitted to the regulator last June. In the VIVID-1 trial, patients treated ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

High-yield dividend stocks can provide crucial retirement income as Social Security benefits face potential cuts. AbbVie, Pfizer, and Chevron combine attractive yields of up to 6.6% with long ...

In the case of the Venezuelans, the DOJ is resisting the kind of meticulous review that it provided in Mahmoud Khalil’s case.

“Aunt Jennifer’s Tigers,” by Adrienne Rich, is a blazing portrait of an artist and her work. Our critic A.O. Scott admires its craft — and its wildness. By A.O. Scott Hisham Matar won ...

Meanwhile, the company expects to deliver high-single-digit annual revenue growth through at least 2029, driven by growing sales of Skyrizi, Rinvoq, and aesthetics. That growth should enable the ...

Join former prosecutor Andy McCarthy as he delves into the legal ins and outs of the latest Washington dramas with National Review editor in chief Rich Lowry. Capital Record – your weekly ...